Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;18(2):80-81.
doi: 10.1038/s41581-021-00521-4.

The COVID-19 pandemic: progress in nephrology

María José Soler  1 , Conxita Jacobs-Cachá  2
Affiliations

The COVID-19 pandemic: progress in nephrology

María José Soler et al. Nat Rev Nephrol. 2022 Feb.

Abstract

Patients with kidney disease are particularly vulnerable to COVID-19. In 2021, key studies demonstrated the safety of renin–angiotensin blockade in patients with kidney failure and COVID-19, and provided new data on the therapeutic potential of soluble angiotensin-converting enzyme, COVID-19 vaccine responses and the long-term effects of COVID-19 on kidney function.

PubMed Disclaimer

Conflict of interest statement

M.J.S. reports grants and personal fees from Novo Nordisk, Janssen, Boehringer, Eli Lilly, AstraZeneca, Esteve, FMC, Mundipharma, Vifor, Bayer, Travere Therapeutics, GE Healthcare and UCI outside the submitted work. C.J.C. reports a grant from Travere Therapeutics outside the submitted work.

Figures

Fig. 1
Fig. 1. New knowledge of COVID-19 and the kidneys in 2021.
a | Renin–angiotensin system (RAS) blockade with either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) is not associated with increased risk or severity of COVID-19 in patients with kidney failure. b | Recombinant ACE2 protein could be a potential therapeutic agent to prevent or treat COVID-19. c | A third dose of the BNT162b2 COVID-19 vaccine increases anti-SARS-CoV-2 spike protein S1 (anti-S1) antibodies in patients with kidney failure on dialysis. d | In addition to the development of acute kidney injury (AKI) during acute COVID-19, the disease can lead to loss of kidney function in the long term. AT1, angiotensin II receptor type 1; eGFR, estimated glomerular filtration rate.
See this image and copyright information in PMC

References

    1. Sparks MA, et al. Sound science before quick judgement regarding RAS blockade in COVID-19. Clin. J. Am. Soc. Nephrol. 2020;15:714–716. doi: 10.2215/CJN.03530320. - DOI - PMC - PubMed
    1. Soler MJ, et al. Association of renin–angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study. Clin. Kidney J. 2021 doi: 10.1093/ckj/sfab161. - DOI - PMC - PubMed
    1. Soler MJ, et al. Renin-angiotensin system blockers and the risk of COVID-19-related mortality in patients with kidney failure. Clin. J. Am. Soc. Nephrol. 2021;16:1061–1072. doi: 10.2215/CJN.18961220. - DOI - PMC - PubMed
    1. Wysocki J, et al. A novel soluble ACE2 variant with prolonged duration of action neutralizes SARS-CoV-2 infection in human kidney organoids. J. Am. Soc. Nephrol. 2021;32:795–803. doi: 10.1681/ASN.2020101537. - DOI - PMC - PubMed
    1. Hassler L, et al. A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infection. bioRxiv. 2021 doi: 10.1101/2021.03.12.435191. - DOI - PMC - PubMed

Publication types